Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature

Posterior reversible encephalopathy syndrome is a rare neurological disorder, the diagnosis of which is based on the combination of clinical and radiological findings. It can be associated with many patient-related conditions such as autoimmune disorders or can be provoked by toxins or medication. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Liapi, Aikaterini, Atat, Chirine, Dunet, Vincent, Sarivalasis, Apostolos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214094/
https://www.ncbi.nlm.nih.gov/pubmed/37250819
http://dx.doi.org/10.1177/2050313X231176401
_version_ 1785047764726448128
author Liapi, Aikaterini
Atat, Chirine
Dunet, Vincent
Sarivalasis, Apostolos
author_facet Liapi, Aikaterini
Atat, Chirine
Dunet, Vincent
Sarivalasis, Apostolos
author_sort Liapi, Aikaterini
collection PubMed
description Posterior reversible encephalopathy syndrome is a rare neurological disorder, the diagnosis of which is based on the combination of clinical and radiological findings. It can be associated with many patient-related conditions such as autoimmune disorders or can be provoked by toxins or medication. We report the case of a 70-year-old patient, known for International Federation of Gynecology and Obstetrics stage IVB, high-grade serous ovarian carcinoma, who was diagnosed with a posterior reversible encephalopathy syndrome while on bevacizumab and olaparib maintenance treatment.
format Online
Article
Text
id pubmed-10214094
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-102140942023-05-27 Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature Liapi, Aikaterini Atat, Chirine Dunet, Vincent Sarivalasis, Apostolos SAGE Open Med Case Rep Case Report Posterior reversible encephalopathy syndrome is a rare neurological disorder, the diagnosis of which is based on the combination of clinical and radiological findings. It can be associated with many patient-related conditions such as autoimmune disorders or can be provoked by toxins or medication. We report the case of a 70-year-old patient, known for International Federation of Gynecology and Obstetrics stage IVB, high-grade serous ovarian carcinoma, who was diagnosed with a posterior reversible encephalopathy syndrome while on bevacizumab and olaparib maintenance treatment. SAGE Publications 2023-05-23 /pmc/articles/PMC10214094/ /pubmed/37250819 http://dx.doi.org/10.1177/2050313X231176401 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Liapi, Aikaterini
Atat, Chirine
Dunet, Vincent
Sarivalasis, Apostolos
Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature
title Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature
title_full Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature
title_fullStr Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature
title_full_unstemmed Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature
title_short Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: A case of PRES and a review of the literature
title_sort dual first-line maintenance by parp inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: a case of pres and a review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10214094/
https://www.ncbi.nlm.nih.gov/pubmed/37250819
http://dx.doi.org/10.1177/2050313X231176401
work_keys_str_mv AT liapiaikaterini dualfirstlinemaintenancebyparpinhibitorandbevacizumabcancauseconfusioninhighgradeserousovariancanceracaseofpresandareviewoftheliterature
AT atatchirine dualfirstlinemaintenancebyparpinhibitorandbevacizumabcancauseconfusioninhighgradeserousovariancanceracaseofpresandareviewoftheliterature
AT dunetvincent dualfirstlinemaintenancebyparpinhibitorandbevacizumabcancauseconfusioninhighgradeserousovariancanceracaseofpresandareviewoftheliterature
AT sarivalasisapostolos dualfirstlinemaintenancebyparpinhibitorandbevacizumabcancauseconfusioninhighgradeserousovariancanceracaseofpresandareviewoftheliterature

Ejemplares similares